Stock KZIA KAZIA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Kazia Therapeutics Limited

Equities

KZIA

US48669G1058

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
0.272 USD -3.72% Intraday chart for Kazia Therapeutics Limited -26.49% -38.11%
May. 01 Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients CI
Apr. 19 Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
PR
Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients
CI
Kazia Therapeutics : Purchase Agreement - Form 6-K
PU
Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP
CI
Kazia Therapeutics : Corporate Presentation
PU
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K
PU
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
PR
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd
CI
Kazia Therapeutics : EVT801 Progress Update Presentation
PU
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
AQ
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study
MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)
AQ
Certain Warrants of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.
CI
Certain Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.
CI
Certain American Depositary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.
CI
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
PR
Kazia Therapeutics Limited Announces Appointment of Board Members
CI
Kazia Therapeutics Limited Announces Resignation of Karen Krumeich as Chief Financial Officer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KZIA Stock
  4. News Kazia Therapeutics Limited